EICHORPublic-registry site landscape for NCT05238597, “A Study to Evaluate the Safety, Tolerability, and Efficacy of A197 in Subjects With Dry Eye Disease”, a Dry Eye Disease study sponsored by Aramis Biosciences, Inc.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT05238597 (registry record) |
| Study title | A Study to Evaluate the Safety, Tolerability, and Efficacy of A197 in Subjects With Dry Eye Disease |
| Official title | A Phase 2, Multicenter, Double-Masked, Randomized, Vehicle-Controlled Clinical Trial Evaluating the Safety, Tolerability, and Efficacy of A197 in Subjects With Dry Eye Disease |
| Sponsor | Aramis Biosciences, Inc. |
| Condition(s) | Dry Eye Disease |
| Phase | PHASE2 |
| Listed sites | 24 |
| Intervention(s) | A197 Ophthalmic Solution, A197 Vehicle Control, Active Comparator |
| Site countries | United States |
Patient-friendly overview of this study: eichor.com/study/NCT05238597.
Eichor generates a preliminary site-risk snapshot for NCT05238597 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
